Gregory Stock is an American biophysicist, best-selling author, biotech entrepreneur, and the former director of the Program on Medicine, Technology and Society at UCLA’s School of Medicine. His interests lie in the scientific and evolutionary as well as ethical, social and political implications of today's revolutions in the life sciences and in information technology and computers.
Life, written works, and business career
Education
He received an MBA from Harvard Business School in 1987, where he was a Baker Scholar and won the Freund-Porter Entrepreneurship award. Stock completed a doctorate in biophysics from Johns Hopkins University in 1977, where he received a BS and MS in 1971.
Biotechnology and its impact on society
He has written extensively on the implications for society, medicine and business of the human genome project and associated developments in molecular genetics and bioinformatics. The Storefront Genome, the symposium he convened in January 2003 to consider the broad challenges that cheap, easy access to our genetic constitutions drew wide media attention, and his 1998 look at the possibilities of manipulating the genetics of human embryos, the first major public discussion of this issue among distinguished scientists, opened a global debate on this then taboo topic.
Biotech entrepreneur
Stock was the CEO of Signum Biosciences. Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation (STM) platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic candidates for Alzheimer's disease, Parkinson's, diabetes, asthma and certain skin conditions. Signum’s STM technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates. Signum was founded on the science derived from basic research studying cellular signaling at the Princeton University laboratory of Dr. Jeffry Stock
He sits on the editorial board of the American Journal of Bioethics and is in the department of Pediatrics at the UCLA School of Medicine. He is a member of the Board of Directors of Napo Pharmaceuticals, a pharmaceutical company headquartered in San Francisco. He sits on the California Advisory Committee on Stem Cells and Reproductive Cloning and serves as the associate director for the Bioagenda Institute and the Center for Life Science Studies at the University of California at Berkeley.
Dr. Stock has been an invited speaker to many academic, government and business conferences. He makes regular appearances on television and radio, and has appeared on CNN, PBS, NPR and the BBC in shows including Talk of the Nation, Charlie Rose, Oprah Winfrey, Biotech Nation and Larry King.
Public policy and activities
Stock was an early force in considering the implications of human germline engineering and human enhancement. Through the Program on Medicine, Technology and Society, which he founded at the UCLA School of Medicine, he organized an influential 1998 conference at UCLA: "Engineering the Human Germline," which included a panel of James Watson, French Anderson, Lee Hood and other major figures in the life sciences. The event, which attracted considerable media attention and opened up broad debate on what was then a largely taboo topic, was covered on the front page of the New York Times. Through another seminal UCLA conference, Milestones on Aging, he organized, Stock helped legitimize research to significantly extend human longevity. The event led to a follow conference he co-hosted at UC Berkeley with Bruce Ames and Aubrey de Grey, who went on to found the Methuselah Foundation, an organization that has aggressively promoted research on life extension. The activity of the MTS Program was also critical in establishing UCLA’s Center on Society and Genetics, which actively explores broad policy issues in the genomics arena.